Boehringer Ingelheim is committing $358 million upfront to gain options on six early-stage oncology programs from Sino Biopharmaceutical, expanding the German drugmaker’s efforts in antibody-drug conjugates and T-cell engagers.
The agreement announced Wednesday covers five programs from Sino’s LaNova Medicines subsidiary and one from its Beijing Tide Pharmaceutical unit. The assets are currently preclinical, meaning they have not yet advanced into human testing under the terms described by the companies.
Deal structure leaves development milestones ahead
Sino will oversee early development of the programs until agreed clinical milestones are reached. At that stage, Boehringer will have options to license the therapies by making additional payments. The arrangement gives Boehringer the opportunity to obtain worldwide rights for two programs and rights outside China for the other four.
| Deal element | Terms |
|---|---|
| Upfront payment | $358 million |
| Programs covered | Six preclinical ADC and TCE programs |
| Potential additional payments | Up to $7 billion in option-exercise fees and milestones |
| Future economics | Tiered royalties if programs reach the market |
| Geographic rights | Worldwide rights for two programs; ex-China rights for four |
Sino could receive as much as $7 billion through option-exercise fees and milestone payments, in addition to tiered royalties if any of the six therapies is commercialized. The stated maximum is therefore dependent on development progress, Boehringer’s exercise of its options and eventual market entry.
“Our second partnership with Boehringer Ingelheim marks an important milestone in SBP Group’s international innovation strategy and further validates our scientific capabilities in next-generation oncology,”
Theresa Tse, chairwoman of SBP Group, said in the company’s release. She added that the partnership would combine Sino’s platforms and early-development capabilities with Boehringer’s global oncology expertise.
Focus on ADCs and T-cell engagers
Antibody-drug conjugates are designed to link an antibody with a drug payload, while T-cell engagers are intended to bring T cells into contact with target cells. The deal gives Boehringer access to both approaches at an early point in development, rather than licensing a program that has already produced clinical data.
Paola Casarosa, who oversees Boehringer’s innovation unit, identified both modalities as a key focus for the company in April. At that time, she said Boehringer would continue examining next-generation payloads and new ways to connect those payloads to antibodies. The company has now added six preclinical programs to that area of research.
The transaction builds on an existing oncology partnership between Boehringer and Sino, which operates globally under the SBP Group brand. Boehringer has also established an External Innovation Hub in Shanghai, giving the German company an existing presence in China’s biopharma ecosystem.
- The agreement covers six preclinical oncology programs.
- Boehringer will pay $358 million upfront and may make additional payments after development milestones.
- Sino could receive up to $7 billion in fees and milestones, plus tiered royalties tied to commercial success.
